公开(公告)号：US20200283515A1

公开(公告)日：2020-09-10

申请号：US16648333

申请日：2018-09-19

Applicant: HUMANITAS MIRASOLE S.P.A. ,  UNIVERSITA' DEGLI STUDI DI MILANO

Inventor： Alberto MANTOVANI ,  Barbara BOTTAZZI ,  Ilaria LAFACE ,  Antonio INFORZATO ,  Tamara GULIC

IPC: C07K16/24 ,  G01N33/68

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

公开(公告)号：US20240123029A1

公开(公告)日：2024-04-18

申请号：US18275776

申请日：2022-02-08

Applicant: HUMANITAS MIRASOLE S.P.A. ,  HUMANITAS UNIVERSITY ,  OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Alberto MANTOVANI ,  Cecilia GARLANDA ,  Barbara BOTTAZZI ,  Elisa VICENZI

IPC: A61K38/17 ,  A61K45/06 ,  A61P31/14 ,  C12Q1/70

CPC classification number: A61K38/178 ,  A61K45/06 ,  A61P31/14 ,  C12Q1/701 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).

公开(公告)号：US20230251274A1

公开(公告)日：2023-08-10

申请号：US18003064

申请日：2021-06-25

Applicant: HUMANITAS MIRASOLE S.P.A. ,  HUMANITAS UNIVERSITY

Inventor： Barbara BOTTAZZI ,  Cecilia GARLANDA ,  Alberto MANTOVANI

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2333/4715

Abstract: The present invention refers to an in-vitro or ex vivo method for the prognosis of a Coronavirus disease and/or for the monitoring of the efficacy of a therapeutic treatment of a Coronavirus disease having the steps of: a) detecting and/or measuring the amount of the protein PTX3 or of fragments thereof or of the polynucleotide coding for the protein or of fragments thereof in an isolated biological sample obtained from the subject Preferably the method further includes—the step: b) comparing the same with a proper control.